Cleared Traditional

K912026 - DELFIA(R) 17 -OH-PROGESTERON KIT

K912026 is an FDA 510(k) clearance for DELFIA 17 -OH-PROGESTERON KIT, manufactured by Pharmacia Diagnostics, Inc.. The device is a Class 1 Hematology device with product code JLX cleared through the Traditional 510(k) pathway after a 49-day FDA review.

K912026 · Pharmacia Diagnostics, Inc. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1991
Decision
49d
Days
Class 1
Risk

K912026 is an FDA 510(k) clearance for the DELFIA(R) 17 -OH-PROGESTERON KIT. Classified as Radioimmunoassay, 17-hydroxyprogesterone (product code JLX), Class I - General Controls.

Submitted by Pharmacia Diagnostics, Inc. (Columbia, US). The FDA issued a Cleared decision on June 25, 1991 after a review of 49 days - a notably fast clearance cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 862.1395 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

FDA 510(k) Submission Details - K912026

510(k) Number K912026 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 07, 1991
Decision Date June 25, 1991
Days to Decision 49 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
64d faster than avg
Panel avg: 113d · This submission: 49d
Pathway characteristics
Predicate-based equivalence.

JLX Device Classification - Class 1, General Controls

Product Code JLX Radioimmunoassay, 17-hydroxyprogesterone
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 862.1395
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.

Regulatory Peers - JLX Radioimmunoassay, 17-hydroxyprogesterone

All 18
Devices cleared under the same product code (JLX) and FDA review panel - the closest regulatory comparables to K912026.
ACCUSCREEN 17-HYDROXYPROGESTERONE
K934178 · Neometrics, Inc. · Mar 1995
NEOSCREEN ELISA HYDROXYPROGESTERONE
K940233 · Pantex · Dec 1994
DSL ACTIVE 17A-OH PROGESTERONE RIA (DSL 5000)
K943148 · Diagnostic Systems Laboratories, Inc. · Nov 1994
NEONATAL BLOOD SPOT TEST 17-HYDROXPROG RADIO KIT
K911839 · Pantex, Div. Bio-Analysis, Inc. · Jun 1991
DSL 17A-OH PROGERSTERONE (DSL #6800)
K894265 · Diagnostic Systems Laboratories, Inc. · Sep 1989
17-ALPHA-HYDROXYPROGESTERONE (17-OH-P) NEO. RIA
K885198 · Icn Biomedicals, Inc. · Feb 1989
K912026 · DELFIA(R) 17 -OH-PROGESTERON KIT
Download PDF Pharmacia Diagnostics…